Alkem Laboratories gains on launching Kojiglo serum in India
Alkem Laboratories is currently trading at Rs. 5170.85, up by 63.60 points or 1.25% from its previous closing of Rs. 5107.25 on the BSE.
The scrip opened at Rs. 5153.85 and has touched a high and low of Rs. 5193.50 and Rs. 5079.70 respectively. So far 260 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6440.00 on 17-Sep-2024 and a 52 week low of Rs. 4409.90 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 5193.50 and Rs. 4992.30 respectively. The current market cap of the company is Rs. 60908.20 crore.
The promoters holding in the company stood at 55.66%, while Institutions and Non-Institutions held 28.16% and 16.18% respectively.
Alkem Laboratories has launched Kojiglo serum in India. This serum is used in managing facial hyperpigmentation and also suitable for all skin types making Alkem, the first Indian company to introduce a liposomal serum with Duo-Lipo technology.
Alkem has its presence in the demelanising category with products like Kojiglo cream, Kojiglo face wash and Kojiglo lotion. According to Strategic Marketing Solutions and Research Centre (SMSRC) data for MAT October 2024, Alkem’s Kojiglo is the number one prescribed brand by dermatologists in the demelanising category. With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
